Proteosomes are becoming important biological targets in drug discovery. For example pathways associated with numerous diseases, such as NF-kB are dependent on proteosomal activation. In the case of NF-kB the proteosomal degradation of phosphorylated IKB is what allows translocation of NF-kB into the nucleus.
In this patent inhibition of the chymotrypsin-like activity proteasomes is claimed as a method of enhancing bone growth and formation.
View this patent on the USPTO website.
You must be signed-in to add your comments.
Sign-in now or Join the StemCellPatents.com Community for free.